当前位置： SCI文献检索 > Current Opinion in Allergy and Clinical Immunology期刊下所有文献 > Gene therapy for adenosine deaminase deficiency.

Gene therapy for adenosine deaminase deficiency.

Abstract：

PURPOSE OF REVIEW:Gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency has moved from the early trials of safety and feasibility to recent studies demonstrating efficacy and clinical benefit. This review describes the latest advances in gene therapy trials for this condition using peripheral blood lymphocytes or hematopoietic progenitors. RECENT FINDINGS:In the first patients with severe combined immunodeficiency due to adenosine deaminase deficiency treated with peripheral blood lymphocytes, transduced T cells have been shown to persist for over 10 years, expressing transgenic adenosine deaminase, but the therapeutic effect of gene therapy remained difficult to assess because of the concomitant treatment with bovine adenosine deaminase conjugated to polyethylene-glycol (PEG-ADA). A recent report showed that discontinuation of PEG-ADA resulted in a strong selective advantage of gene corrected T cells associated with restoration of T cell functions and antibody responses to neoantigen, but incomplete correction of the metabolic defect. Follow-up studies in patients treated with engineered hematopoietic progenitors in the early trials revealed low marking levels of long-term living progenitors and limited clinical effect. Recently, an improved gene transfer protocol in bone marrow CD34+ cells combined with low-dose busulfan resulted in multilineage, stable engraftment of transduced progenitors at substantial levels, restoration of immune functions, correction of the adenosine deaminase metabolic defect, and proven clinical benefit, in the absence of PEG-ADA. Overall, no adverse effect or toxicity has been observed in patients treated with adenosine deaminase gene transfer in mature lymphocytes or hematopoietic progenitors. SUMMARY:Gene transfer in hematopoietic stem cells combined with nonmyeloablative conditioning is efficacious and might be extended to the treatment of other inherited and acquired disorders of the hematopoietic system.

journal_name

Curr Opin Allergy Clin Immunol

journal_title

Current opinion in allergy and clinical immunology

authors

Aiuti A,Ficara F,Cattaneo F,Bordignon C,Roncarolo MG

doi

10.1097/00130832-200312000-00007

keywords:

subject

Has Abstract

pub_date

2003-12-01 00:00:00

pages

461-6

issue

eissn

1528-4050

issn

1473-6322

pii

00130832-200312000-00007

journal_volume

pub_type

杂志文章,评审

在线工具

Gene therapy for adenosine deaminase deficiency.